Company profile
Merz Therapeutics
Privately held: no public share price
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Fampridine(Ampyra / Fampyra) | Approved | Potassium Channel Blocker · Voltage-gated potassium channel (Kv) · Voltage-gated potassium channels (Kv1/Shaker/KCNA family)Small molecule | Multiple Sclerosis |
| Approved | dopamine precursorSmall molecule | Parkinson's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.